The 60% sell off was essessentially triggered by the comment that the secondary endpoint saw no overall difference. This is notwithstanding the fact that there was a 15% infarct volume reduction or efficacy in slow collateral patients. This is the key takeaway and its important. It follows that these slow collateral patients are the worst affected. The rest could well make a healthy recovery, or at least a substantially better one than the slow collateral ones. For them, a 15% improvement is very meaningful...much much higher than what we have now and will make a very significant difference to that patient cohort ongoing recovery. Now here is where it gets interesting. The drug is proven in safety. It can be taken with other drugs. There is nothing to stop stroke victims getting the drug from first responders...or on arrival at hospital. AG007 will have a significant impact on that 30% cohort. It will get the whole market... I think I know who the Phase 2B will be aimed at. Recruitment wont be an issue and the outcome of the 2B will be, most likely, a success....and a huge market still awaits. This stock is cheap.
AGN Price at posting:
24.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)